Management of toxicities of immune checkpoint inhibitors
Immune checkpoint inhibition with the anti-CTLA-4 antibody ipilimumab and the anti-PD-1
antibodies nivolumab and pembrolizumab has improved survival in metastatic melanoma, …
antibodies nivolumab and pembrolizumab has improved survival in metastatic melanoma, …
Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with …
S Diem, S Schmid, M Krapf, L Flatz, D Born, W Jochum… - Lung cancer, 2017 - Elsevier
Objectives Immunotherapy with the programmed death receptor-1 (PD-1) antibody
nivolumab has changed the field of metastatic non-small cell lung cancer (NSCLC) treatment. …
nivolumab has changed the field of metastatic non-small cell lung cancer (NSCLC) treatment. …
Association of checkpoint inhibitor–induced toxic effects with shared cancer and tissue antigens in non–small cell lung cancer
Importance Immunotherapy with checkpoint inhibitors targeting the PD-1 (programmed cell
death 1) axis has brought notable progress in patients with non–small cell lung cancer (…
death 1) axis has brought notable progress in patients with non–small cell lung cancer (…
[PDF][PDF] Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors
Background Immune checkpoint inhibitors (ICIs) are among the most promising treatment
options for melanoma and non-small cell lung cancer (NSCLC). While ICIs can induce …
options for melanoma and non-small cell lung cancer (NSCLC). While ICIs can induce …
[HTML][HTML] Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
Background Checkpoint inhibitors (CIs) are highly effective but can induce severe immune-related
adverse events (irAEs), which cannot be predicted. We investigated whether human …
adverse events (irAEs), which cannot be predicted. We investigated whether human …
Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer
O Hasan Ali, S Diem, E Markert, W Jochum… - …, 2016 - Taylor & Francis
Immune checkpoint inhibitors have led to considerable therapy improvement in cancer patients.
Autoimmune side effects including skin reactions are frequently observed. In melanoma, …
Autoimmune side effects including skin reactions are frequently observed. In melanoma, …
Autoreactive napsin A–specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade
…, S Haen, T Gross, MT Abdou, S Diem… - Science …, 2022 - science.org
Cancer treatment with immune checkpoint blockade (ICB) often induces immune-related
adverse events (irAEs). We hypothesized that proteins coexpressed in tumors and normal cells …
adverse events (irAEs). We hypothesized that proteins coexpressed in tumors and normal cells …
[HTML][HTML] C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer
…, J Ellinger, P Brossart, S Diem… - … for Immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Biomarkers for predicting response to anti-programmed death-1 (PD-1) immune checkpoint
blockade (ICB) in non-small cell lung cancer (NSCLC) remain in demand. Since anti-tumor …
blockade (ICB) in non-small cell lung cancer (NSCLC) remain in demand. Since anti-tumor …
Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)
S Schmid, S Diem, Q Li, M Krapf, L Flatz… - Cancer Immunology …, 2018 - Springer
Background Response to immune checkpoint inhibitors depends on tumor intrinsic
properties and also on host factors in the tumour microenvironment including the presence of …
properties and also on host factors in the tumour microenvironment including the presence of …
[HTML][HTML] BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with …
…, SS Ring, F Berner, M Fässler, S Diem… - Journal of the American …, 2020 - Elsevier
Background Anti-programmed cell death protein 1 (PD1)/programmed death-ligand 1(PD-L1)
therapy frequently entails immune-related adverse events (irAEs), and biomarkers to …
therapy frequently entails immune-related adverse events (irAEs), and biomarkers to …